Chorionic Villus Sampling Doesn't Increase Fetal Loss
No statistically significant difference in fetal loss between those with and without CVS
TUESDAY, Oct. 7 (HealthDay News) -- Fetal loss is no different among women undergoing chorionic villus sampling (CVS) than among women who do not undergo an invasive procedure during early pregnancy, according to research published in the October issue of Obstetrics & Gynecology.
Anthony O. Odibo, M.D., of the Washington University School of Medicine in St. Louis, and colleagues performed a retrospective cohort study examining fetal loss rate and associated risk factors following CVS. Both univariable and multiple logistic regression analyses were used to compare CVS and control pregnancies for fetal loss and adjust for confounders.
Among 5,243 women who had CVS there were 138 fetal losses (2.7 percent) before 24 weeks' gestation, while among 4,917 women who did not undergo an invasive procedure there were 161 fetal losses (3.3 percent) before 24 weeks' gestation, the researchers report. The difference in fetal loss was not statistically significant. The investigators found that significant risk factors for fetal loss included African-American maternal race, two or more aspirations/needle insertions, heavy bleeding during CVS, mother's age under 25 years, and CVS performed before 10 weeks' gestation.
"In conclusion, our study found the loss rate from CVS to be comparable to that in women who had no procedure," the authors write. "Significant predictors of fetal loss after CVS were identified, but the accuracy of the final model for predicting fetal loss was only modest."